Skip to main content
. Author manuscript; available in PMC: 2013 Apr 12.
Published in final edited form as: Curr Opin Oncol. 2012 Mar;24(2):191–196. doi: 10.1097/CCO.0b013e32834f5c27

Table 1.

Randomized Comparisons of Allogeneic PBSC v. BM

Total No. Pts % Patients with Advanced Disease4 Stem Cell Source Engraftment: Median Day to: Acute GVHD % Chronic GVHD % DFS3 % Survival %
Neutrophils5 00/ul Platelets 20,000/ul Grade II–IV Grade III–IV
[19] 101 5 PBSC
BM		 15*
21		 13*
21		 44
42		 17
23		 50*
28		 58
62		 61
61
[20] 611 28 PBSC
BM		 17*
23		 13*
21		 25
10		 NR 55
26		 85
65		 82
75
[21]
[22]		 56 32 PBSC
BM		 15*
18		 12*
18		 26
23		 13
13		 77*
61		 60
50		 56
48
[23] 30 NR2 PBSC
BM		 9*
25		 10*
30		 7
40		 7
40		 NR NR NR
[24]
[25]		 329 14 PBSC
BM		 12*
15		 15*
20		 52*
39* 		28*
16		 74*
53		 425
45		 495
57
[26] 39 46 PBSC
BM		 17*
23		 11*
19		 50
47		 NR 44
40		 NR 70
63
[27] 2281 27 PBSC
BM		 19*
22		 16*
22		 40
40		 NR 71
55		 NR 68*
60
[28]
[29]		 172 47 PBSC
BM		 16*
21		 13*
19		 64
57		 15
12		 48
38		 655*
45		 585
56
1

6 donor-recipients were 5/6 antigen matches

2

NR = not reported

3

DFS = disease -free survival

4

Advanced disease = CML >CP, Acute leukemias >1st CR, Lymphomas >2nd CR, RAEB(T), multiple myeloma

5

10 year outcomes

*

= statistically significant